Single Arm, Open, Phase II Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Pancreatic Neoplasms
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Catequentinib (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; TQB 2868 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical
- 16 Jan 2025 New trial record